OTC Markets OTCPK - Delayed Quote USD

Bayer Aktiengesellschaft (BAYRY)

Compare
5.06 -0.01 (-0.20%)
At close: January 8 at 3:00:00 PM EST
Loading Chart for BAYRY
DELL
  • Previous Close 5.07
  • Open 5.00
  • Bid 5.06 x 40000
  • Ask 5.07 x 40000
  • Day's Range 4.96 - 5.07
  • 52 Week Range 4.79 - 9.47
  • Volume 104,135
  • Avg. Volume 1,792,664
  • Market Cap (intraday) 20.183B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.23
  • Earnings Date Mar 5, 2025
  • Forward Dividend & Yield 0.03 (0.58%)
  • Ex-Dividend Date Apr 29, 2024
  • 1y Target Est 7.59

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.

www.bayer.com

96,931

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BAYRY

View More

Performance Overview: BAYRY

Trailing total returns as of 1/9/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

BAYRY
3.69%
DAX P
2.16%

1-Year Return

BAYRY
47.68%
DAX P
21.67%

3-Year Return

BAYRY
60.47%
DAX P
27.53%

5-Year Return

BAYRY
71.39%
DAX P
52.69%

Compare To: BAYRY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BAYRY

View More

Valuation Measures

As of 1/8/2025
  • Market Cap

    19.98B

  • Enterprise Value

    53.38B

  • Trailing P/E

    --

  • Forward P/E

    1.47

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.41

  • Price/Book (mrq)

    0.63

  • Enterprise Value/Revenue

    1.10

  • Enterprise Value/EBITDA

    5.51

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -1.88%

  • Return on Assets (ttm)

    5.11%

  • Return on Equity (ttm)

    -2.73%

  • Revenue (ttm)

    46.74B

  • Net Income Avi to Common (ttm)

    -880M

  • Diluted EPS (ttm)

    -0.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.62B

  • Total Debt/Equity (mrq)

    134.10%

  • Levered Free Cash Flow (ttm)

    3.33B

Research Analysis: BAYRY

View More

People Also Watch